Epidemiology of adenoid cystic carcinoma in the United States.

Author:

Boyle Tirza Areli Calderón1,St. Laurent Samantha2,Semus Simon1,Joseph Nedra1

Affiliation:

1. GlaxoSmithKline, Collegeville, PA;

2. GlaxoSmithKline, Waltham, MA;

Abstract

e13600 Background: Adenoid cystic carcinoma (ACC) is a rare malignancy of the secretory glands, accounting for approximately 1% of head and neck cancers and 10% of salivary gland neoplasms. ACC primarily occurs in the major and minor salivary glands; however, it is found in other sites of the head and neck, breast, female genital tract, prostate and skin. There is limited scientific literature on the epidemiology of ACC and no published incidence or prevalence estimates across all anatomic sites. Methods: Using data from the Surveillance, Epidemiology, and End Results (SEER) 18 registries, ACC cases were identified by International Classification of Diseases for Oncology 3rd Edition histology codes. Data from 2012-2016 were used to estimate age-adjusted incidence rates (IR) and 5-year limited duration prevalence (LDP). Data from 2000-2016 were used to approximate 16-year LDP. IR and LDP were estimated overall and by age, sex and race. IR was calculated for each anatomic site. Total incident and prevalent cases were projected using the 2020 US Census population. Analyses were conducted in SEER*Stat (v8.3.6) and SAS 9.4. Results: In the US, ACC age-adjusted IR was 0.35 per 100,000 and 5- and 16-year LDP were 1.48 and 3.24 per 100,000, respectively (Table). ACC IR and LDP (per 100,000) were highest in those aged 75-79 years (IR 1.45; 5-year LDP 5.82; 16-year LDP 14.25) and in females, and lowest among Native Americans/Alaska Natives. ACC IR (per 100,000) were highest in the oral cavity and pharynx (IR 0.19), salivary glands (IR 0.12), respiratory system (IR 0.07) and breast (IR 0.05). As of January 1, 2020, 10,777 patients were living with ACC in the US who had been diagnosed 2000-2016. Conclusions: This study describes the US epidemiology of ACC across all anatomic sites and provides incidence and prevalence estimates not currently published in the literature. Improving understanding of the epidemiology of this rare cancer has important implications for the development of effective clinical and public health interventions. [Table: see text]

Funder

GlaxoSmithKline

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3